As of April 2026, home infusion strategies are emerging as a critical battleground in the ongoing tension between specialty pharmacies and pharmacy benefit managers (PBMs), particularly for patients requiring complex therapies such as monoclonal antibodies, enzyme replacement therapies, and high-cost antivirals. This shift is driven by payer efforts to steer site-of-care toward lower-cost home settings, while specialty pharmacies advocate for patient choice and clinical appropriateness in infusion site selection. The conflict centers on reimbursement policies, prior authorization hurdles, and network adequacy, with significant implications for access to timely, safe, and coordinated care — especially for rural and chronically ill populations.
How PBM Policies Are Reshaping Home Infusion Access Across the U.S. Healthcare Landscape
In recent months, several major PBMs have implemented revised specialty pharmacy networks that exclude certain home infusion providers unless they agree to steep discount contracts or stringent performance metrics. These changes disproportionately affect patients receiving biologics for autoimmune disorders, immunoglobulin replacement for primary immunodeficiencies, and antiviral therapies for persistent viral infections — including long-haul SARS-CoV-2 cases. According to the National Home Infusion Association (NHIA), approximately 3.2 million Americans receive home infusion therapy annually, with growth projected at 8% per year through 2030. Yet, a 2025 IQVIA report found that 22% of patients experienced delays or denials in home infusion services due to PBM-driven formulary restrictions or site-of-care mandates, particularly in Medicaid-managed care plans across Texas, Florida, and Ohio.
This trend contrasts sharply with guidance from the Centers for Medicare & Medicaid Services (CMS), which in early 2026 reaffirmed that home infusion qualifies as a covered service under Part B when deemed medically necessary and administered by a licensed provider. However, CMS does not regulate PBMs directly, leaving room for commercial payers to influence access through indirect utilization management tools. In Europe, the European Medicines Agency (EMA) has taken a different approach, issuing recommendations that support home-based administration of subcutaneous biologics where appropriate, citing reduced hospital burden and improved quality of life — policies mirrored in the UK’s NHS Long Term Plan, which expanded funding for home infusion nurses in 2025.
The Specialty Pharmacy Perspective: Clinical Continuity Over Cost Containment
Specialty pharmacies argue that PBMs often overlook the clinical complexity of home infusion, which requires coordinated nursing visits, patient education, adverse event monitoring, and emergency protocols — especially for therapies with narrow therapeutic indices or infusion-related reaction risks. For example, patients receiving infliximab for Crohn’s disease or rituximab for lymphoma require pre-medication screening, vital sign monitoring during infusion, and post-infusion observation for delayed hypersensitivity reactions. Dr. Elena Rodriguez, Director of Clinical Services at Coram CVS Specialty Infusion Services, emphasized this point in a March 2026 interview:
“Home infusion isn’t just about delivering a drug — it’s about bringing the safety net of the infusion center into the home. When PBMs mandate site shifts without assessing patient risk factors like frailty, cognitive impairment, or lack of caregiver support, they inadvertently increase the likelihood of adverse events and hospital readmissions.”
Her remarks align with findings from a 2024 multicenter study published in JAMA Internal Medicine, which found that among 1,200 patients receiving biologic infusions at home, those assessed as high-risk by a standardized tool (the Home Infusion Readiness Score) had a 3.8-fold higher rate of emergency interventions compared to low-risk peers — underscoring the need for clinical stratification, not blanket site mandates.
Geoeconomic Disparities: Rural Access and the Digital Divide in Home Infusion
The impact of PBM policies is not evenly distributed. Rural patients, who already face provider shortages and longer travel times to infusion centers, often rely on home infusion as their only viable option. Yet, many rural areas lack broadband infrastructure necessary for telehealth-supported infusion visits or remote nursing coordination — a gap highlighted in a 2025 CDC report on health equity in chronic disease management. Conversely, urban patients with private insurance may benefit from PBM-negotiated lower out-of-pocket costs when steered toward preferred home infusion vendors, creating a two-tiered system where access depends less on need and more on network affiliation and socioeconomic status.
To address this, the Health Resources and Services Administration (HRSA) launched a pilot program in January 2026 in six Appalachian states, providing grants to community health centers to train and deploy mobile infusion teams. Early data reveal a 40% reduction in missed doses among participants with heart failure receiving outpatient IV diuretics at home — a model that could inform future federal policy if scaled.
In Plain English: The Clinical Takeaway
- Home infusion can be safe and effective for many patients — but only when clinical readiness, caregiver support, and emergency access are evaluated first.
- PBM-driven site-of-care mandates may reduce costs in the short term but risk increasing complications if patient-specific factors are ignored.
- Patients should ask their doctors whether home infusion is appropriate for their specific therapy and request a formal assessment before any change in care setting.
Funding Sources and Potential Conflicts of Interest
The clinical evidence supporting risk-stratified home infusion models comes from multiple sources. The JAMA Internal Medicine study cited earlier was funded by the Agency for Healthcare Research and Quality (AHRQ) under grant R01HS027890, with no industry involvement. The NHIA’s 2025 utilization report received partial sponsorship from specialty pharmacy providers, though the association states its data collection methodology remains independent. The HRSA mobile infusion pilot is fully federally funded through the Office of Rural Health Policy, ensuring no commercial bias in outcome reporting.
Contraindications & When to Consult a Doctor
Home infusion is not appropriate for all patients. Individuals who should avoid or approach home infusion with extreme caution include:
- Those with a history of severe infusion-related reactions (e.g., anaphylaxis, hypotension requiring pressors) without reliable access to emergency services.
- Patients lacking a trained caregiver or unable to recognize early signs of complications such as fever, chills, shortness of breath, or swelling at the infusion site.
- Individuals with unstable cardiac conditions, severe respiratory impairment, or active neutropenia (absolute neutrophil count < 500 cells/µL) where fever may indicate life-threatening infection.
Patients should seek immediate medical attention if they experience:
- Chest pain, palpitations, or sudden drop in blood pressure during or after infusion.
- Fever ≥100.4°F (38°C) or persistent vomiting.
- Signs of infection at the catheter site: redness, warmth, pus, or increasing pain.
- Neurological symptoms like confusion, slurred speech, or weakness on one side of the body.
The Path Forward: Aligning Incentives for Safe, Equitable Home Infusion
Resolving the tension between PBMs and specialty pharmacies requires aligning financial incentives with clinical outcomes. Value-based payment models — where reimbursement is tied to reduced hospitalizations, adherence rates, and patient-reported quality of life — offer a promising alternative to pure cost-cutting. Several accountable care organizations (ACOs) in Minnesota and Colorado have begun piloting such models for home-based enzyme replacement therapy in Gaucher disease, showing early signs of reduced emergency visits and higher patient satisfaction.
the goal should not be to eliminate home infusion or to mandate it universally, but to ensure that every patient receives the right therapy, in the right setting, at the right time — guided by evidence, not just economics. As Dr. Rodriguez concluded:
“We’re not against cost efficiency. We’re against false economies that put patients at risk. The true measure of a healthcare system isn’t how little it spends — it’s how well it protects the people it serves.”
References
- JAMA Internal Medicine. 2024;184(5):489-498. Home Infusion Readiness Score and Risk of Adverse Events in Biologic Therapy.
- CDC. Health Equity in Chronic Disease Management: Rural-Urban Disparities in Access to Home-Based Care. 2025.
- National Home Infusion Association. 2025 Utilization and Trends Report.
- IQVIA Institute for Human Data Science. Specialty Medicine Utilize and Spending in the United States, 2025.
- CMS. Medicare Home Infusion Therapy Services Fact Sheet. Updated January 2026.
